Struggling CTI gets a mixed bag of PhIII results for a lead drug still under a full hold at the FDA
With its stock firmly planted in penny territory, the struggling CTI BioPharma $CTIC revealed that its top asset pacritinib achieved mixed results in a Phase III study, hitting one endpoint and missing another according to preliminary numbers. The drug, though, was put on a full clinical hold back in February, after the FDA took a look at new data indicating that patients in the drug arm were dying faster than subjects in the control arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.